Barinthus Biotherapeutics plc
BRNS
$0.73
$0.011.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 14.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 14.97M |
| Cost of Revenue | 5.22M | -1.00K | 7.96M | 69.00K | 10.93M |
| Gross Profit | -5.22M | 1.00K | -7.96M | -69.00K | 4.04M |
| SG&A Expenses | 5.31M | 15.38M | 12.97M | -3.37M | 14.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -72.00K | -13.00K | -29.00K | -184.00K | -- |
| Total Operating Expenses | 10.23M | 21.98M | 20.60M | 2.67M | 24.33M |
| Operating Income | -10.23M | -21.98M | -20.60M | -2.67M | -9.36M |
| Income Before Tax | -14.64M | -21.15M | -19.68M | -20.59M | -8.13M |
| Income Tax Expenses | -71.00K | -25.00K | -22.00K | 3.00K | -3.00K |
| Earnings from Continuing Operations | -14.57M | -21.13M | -19.66M | -20.59M | -8.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.00K | 2.00K | 10.00K | 51.00K | 15.00K |
| Net Income | -14.57M | -21.12M | -19.65M | -20.54M | -8.11M |
| EBIT | -10.23M | -21.98M | -20.60M | -2.67M | -9.36M |
| EBITDA | -10.13M | -20.78M | -19.36M | -2.04M | -8.69M |
| EPS Basic | -0.36 | -0.52 | -0.49 | -0.51 | -0.21 |
| Normalized Basic EPS | -0.15 | -0.33 | -0.31 | -0.03 | -0.14 |
| EPS Diluted | -0.36 | -0.52 | -0.49 | -0.51 | -0.21 |
| Normalized Diluted EPS | -0.15 | -0.33 | -0.31 | -0.03 | -0.14 |
| Average Basic Shares Outstanding | 40.66M | 40.34M | 40.27M | 40.16M | 39.42M |
| Average Diluted Shares Outstanding | 40.66M | 40.34M | 40.27M | 40.16M | 39.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |